PATENT CLAIM ANALYSIS

Application Number: 16125373
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "292000"]

Abstract:
The present invention relates to certain PDE2 inhibitory compounds, in free or salt form, pharmaceutical compositions containing such compounds and methods for the treatment of PDE2 mediated disorders.

Claim (Index 4):
The compound according to  claim 1 , wherein the compound is selected from the group consisting of:\n 1-(5-Butoxy-2-fluorophenyl)-8-(4-fluorophenoxy)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(5-Butoxy-2-fluorophenyl)-8-(dimethylamino)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(pyrrolidin-1-yl)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(1H-pyrazol-1-yl)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(5-Butoxy-2-fluorophenyl)-3-methyl-8-(pyridin-2-ylamino)-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(5-Butoxy-2-fluorophenyl)-8-(ethylthio)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carbonitrile; 1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylicacid; Ethyl 1-(5-butoxy-2-fluorophenyl)-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxylate; 1-(5-Butoxy-2-fluorophenyl)-N-ethyl-3-methyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide; 1-(5-Butoxy-2-fluorophenyl)-3-methyl-4-oxo-3a,4-dihydro-1H-pyrazolo[4,3-c][1,5]naphthyridine-8-carboxamide; 8-Chloro-1-(2-chloro-5-(cyclopropylmethoxy)phenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(2,5-Dichlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(2-Chlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][ 1,5]naphthyridin-4(5H)-one; 1-(2-Chlorophenyl)-3 ,5-dimethyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(2,5-Dichlorophenyl)-3 ,5-dimethyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(5-Butoxy-2-chlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(5-Butoxy-2-fluorophenyl)-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 8-Chloro-1-(2,5-dichlorophenyl)-3-methyl-1H-pyrazolo[4,3-c][ 1,5]naphthyridin-4(5H)-one; 1-(5-Butoxy-2-chlorophenyl)-8-chloro-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; 1-(5-Butoxy-2-chlorophenyl)-8-methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; and 1-(2-Chloro-5-(cyclobutylmethoxy)phenyl)-8-methoxy-3-methyl-1H-pyrazolo[4,3-c][1,5]naphthyridin-4(5H)-one; in free or salt form.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 97.0
- Lexical Diversity: 1.10714
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15533525', '13128726', '15533527', '11991858', '15502144']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7937014834725866
- 35 USC 102 Novelty (BERT): 0.6241149174907745
- Combined Prediction Score: 0.7767428268744054
- Mean Citation Score: 385.984218
- Max Citation Score: 554.9456
- Similarity Product: 534.5307978546142

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test